| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8cfdaa239a0512b2e50cfe53290cb51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D489-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D489-08 |
| filingDate |
2015-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a98e72f27d1827ab3bc8abcfad384a5 |
| publicationDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10017519-B2 |
| titleOfInvention |
Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
| abstract |
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxycodone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10449190-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10696683-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11020386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017196851-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10695342-B2 |
| priorityDate |
2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |